Results of unrelated cord blood transplant in patients with bone marrow failure syndromes  by Gluckman, E.
serve as a demonstration that cord blood cells can differentiate into
non-hematopoietic tissues.
All children were prepared for transplant with myeloablative
chemotherapy consisting of busulfan, cyclophosphamide and anti-
thymocyte globulin. Prophylaxis against GvHD was administered
with cyclosporine and methylprednisolone. Supportive care was
provided with IVIG, G-CSF, low dose heparin for VOD prophy-
laxis, leukocyte depleted and irradiated PRBC and platelet trans-
fusions, total parenteral nutrition, prophylactic antiviral and anti-
fungal antibiotics and empiric antibiotic therapy for fever. Thirty
ﬁve young children with Hurler syndrome (MPS I) were trans-
planted with partially HLA mismatched unrelated donor umbilical
cord blood over the past 8 years. All had the severe phenotype.
Neutrophil (ANC 500/	L) and platelet (50k/	L) engraftment
occurred in a median of 20 and 63 days respectively. Moderate to
severe acute GvHD occurred in 28 % of patients. Extensive
chronic GvHD was not seen. Twelve percent of patients had
serious events, graft rejection (n  1), infectious deaths (n  3),
toxic death (n 1, hyperammonemia). All other patients (87%) are
surviving event-free for a median greater than 3 years. All surviving
children remain full donor chimeras and have shown increasing
velocities of gains of neurocognitive functions. Skeletal growth
improved with only 4/11 children with severe kyphosis requiring
orthopedic surgery post transplantation therapy. No child devel-
oped clinical cardiac disease and corneal clouding improved in all.
Additional children (60) with lysosomal storage diseases includ-
ing metachromatic leukodystrophy, adrenoleukodystrophy and
globoid leukodystrophy (Krabbe disease) have been transplanted
with unrelated donor umbilical cord blood over the past 9 years. In
asymptomatic children, disease was arrested before the onset of
neurologic dysfunction. In symptomatic children disease progres-
sion was arrested within 6-9 months of the transplant procedure. In
a child with advanced Krabbe disease who died 1 year post trans-
plant, engraftment of donor cells was noted in the brain. Differ-
entiation to oligodendrocytes was demonstrated in vitro and sub-
sequently, in vivo. In a child with MPS III (Sanﬁlippo syndrome),
donor cells differentiated into cardiac myocytes in the heart 6
months post transplant.
These studies suggest that cord blood is capable of transdiffer-
entiation into non-hematopoietic lineages. Further studies are
needed to fully deﬁne the potential of these cells for cellular
therapies and tissue repair.
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UNRELATED DONOR CORD BLOOD TRANSPLANTATION FOR CHILDREN
WITH HEMATOLOGICAL MALIGNANCIES
Zecca, M., Locatelli, F. Pediatric Hematology, IRCCS Policlinico San
Matteo, Pavia, Italy.
Cord blood (CB) contains a large amount of hematopoietic
progenitors and over the last decade has been largely employed to
transplant children with either malignant or non-malignant disor-
ders. Advantages related to the use of CB cells are represented by
the low risk of acute and chronic graft-versus-host disease
(GVHD), prompt availability of this source of hematopoietic pro-
genitors, which shortens the time needed to locate a suitable
donor, and by the possibility of performing transplants in the
presence of 1 or 2 HLA disparities in the donor/recipient pairs.
Both these latter two factors can be relevant for treating children
with malignancies, whose disease, often running an aggressive
clinical course, might not allow an extended period of time for
ﬁnding a suitable unrelated bone marrow donor. Hundreds of
children with acute lymphoblastic or myeloid leukemia have re-
ceived an allograft of unrelated CB cells. The experience derived
from these patients has demonstrated that results achieved with
this type of transplant are substantially comparable to those ob-
tained in children given bone marrow transplantation. In particu-
lar, the risk of leukemia recurrence is not increased after CB
transplantation. Disease status at time of transplantation is the
main factor inﬂuencing patient’s outcome, patients transplanted in
1st-2nd remission being those with the best results. Both a higher
transplant-related mortality and an increased risk of leukemia re-
currence contribute to the worse outcome of patients given the
allograft in more advanced disease. As most deaths occurring in
children given CB transplantation are due to infectious complica-
tions (related to both delayed hematopoietic recovery and lack of
adoptive transfer of memory T-cells) strategies able to accelerate
both hematopoietic and immune reconstitution could widen the
use of CB cells for transplantation.
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THE ROLE OF CORD BLOOD TRANSPLANTATION IN THALASSEMIA
Walters, M. Oakland Children’s Hospital, Oakland, CA.
More than 20 years ago, the ﬁrst successful cure of 
-thalassemia
major by bone marrow transplantation was reported. Since then,
more than 1500 patients have been treated in this manner. In
Pesaro Italy where more than 1000 patients have received marrow
transplantation, the 20-year probability of thalassemia-free survival
is approximately 70%. Updated results strongly suggest that im-
proved outcomes across risk categories have occurred as effective
supportive care and conditioning regimen modiﬁcations have been
applied to this setting. As with other non-malignant conditions, the
alternative of increasingly effective supportive care also impacts
upon the decision to pursue transplantation, even when transplant
outcomes are very good. Umbilical cord blood (UCB) transplan-
tation, thus, must compare favorably to proven therapeutic alter-
natives before its use can be expanded. UCB is an attractive alter-
native to other stem cell sources due to its decreased incidence of
graft-versus-host disease (GVHD) and rapid tempo of immuno-
logical reconstitution after transplantation. Initial results of UCB
transplantation for thalassemia suggest that acceptable out-
comes are possible if measures are taken to mitigate the risk of
graft rejection. Among 44 patients with sickle cell disease or
thalassemia who received augmented conditioning therapy, the
event-free survival was 94% compared to 62% among those who
received a standard combination of busulfan and cyclophosph-
amide, with or without horse anti-thymocyte globulin. These
early results also support the importance of banking efforts to
expand the collection of related and unrelated UCB units. The
clinical experience of unrelated UCB transplantation for thalas-
semia remains very limited. New techniques to prevent GVHD
and promote engraftment, coupled with reﬁned donor selection
criteria should expand the availability of transplantation for
thalassemia major.
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RESULTS OF UNRELATED CORD BLOOD TRANSPLANT IN PATIENTS
WITH BONE MARROW FAILURE SYNDROMES
Gluckman, E. Eurocord, Hospital Saint Louis, Paris, France.
In Fanconi anemia (FA) patients without an HLA identical bone
marrow donor, search for an unrelated cord blood donor is an
option, however few results have been reported so far. In the
Eurocord registry, we have analyzed 44 patients with FA receiving
an unrelated cord blood transplant (UCBT). The median age was
7.7 years and median follow-up 20 months (8-83). At UCBT, the
median number of neutrophils was 620/mm3 and 13 patients had
received more than 20 red blood cell transfusions. The cord blood
was HLA mismatched in 37 patients (HLA-A and B by serology
and DRB1 high resolution typing, 5/6  21, 4/6  12 and 3/6 
3). The median number of nucleated cells (NC) at freezing was 5.5
 107/kg and at infusion 4.7  107/kg. Eighteen patients received
CY and irradiation based preparative regimens, 12 patients ﬂudara-
bine (FLU) containing regimen, 6 CY alone and 8 other regimens.
GVHD prophylaxis consisted of CSA and MTX (43%) or CsA
alone (23%). Results: Neutrophil recovery at day 60 was 56% 
8%. Two factors were associated with higher probability of neu-
trophil recovery (cell dose and number of HLA disparities). Acute
GVHD (II-IV) was 23%  6% (grade II  7%, III  7%, IV 
11%) and chronic GVHD occurred in 4/21 patients at risk (19%).
Two year survival was 36%  7%. In univariate analysis factors
associated with better survival were negative CMV serology,
NC at freezing or infused, higher neutrophil count at UCBT
and FLU containing regimen. In multivariate analysis only two
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factors were associated with better survival: NC at freezing
(5.5  107/kg) (HR  0.25, p  0.004) and FLU containing
preparative regimen (HR  0.16, p  0.018). In patients re-
ceiving a higher cell dose, 2-y survival was 55% versus 16% for
those receiving a lower dose (p  0.005); it was 67% for those
receiving a FLU containing regimen compared to 25% (p 
0.016) for those receiving other regimens. We conclude that
results of UCBT for FA patients are acceptable and can be
improved by better selection of the CB units and use of FLU in
the preparative regimen.
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THE ROLE OF CD4CD25 T REGULATORY (TREG) CELLS IN ALLOGE-
NEIC BONE MARROW TRANSPLANTATION
Blazar, B.R.1, Panoskaltsis-Mortari, A.1, Levine, B.L.2, June, C.H.2,
Lucas, P.J.3, Gress, R.3, Serody, J.S.4, Taylor, P.A.1, 1. Pediatrics,
Univ. Minn, Minneapolis, MN; 2. Cancer Center, Univ. Penn, Phila-
delphia, PA; 3. NCI, Bethesda, MD; 4. Medicine, Microbiology and
Immunology and the Lineberger Comprehensive Cancer Center, UNC-
Chapel Hill, Chapel Hill, NC.
A subpopulation of CD4 T cells that co-expresses CD25, the
IL-2 receptor alpha chain, without evidence of prior activation, has
been shown to be important in self-tolerance by suppressing au-
toimmune responses. These CD4CD25 Treg cells are present
in rodents at a frequency of 8-12% of CD4 T cells and in humans
at lower frequencies (1-4%). In vitro, Treg cells are potent inhib-
itors of alloresponses. Depletion of either host CD25 cells prior
to BMT or donor CD25 cells in the donor graft inoculum
present markedly accelerated graft-versus-host disease (GVHD)
lethality. Whereas supplementing the donor graft with fresh
CD4CD25 Treg cells delayed GVHD lethality, adding ex vivo
activated and expanded Treg cells virtually abolished GVHD le-
thality. These data are consistent with the fact that activated Treg
cells are more potent suppressors than non-activated cells. In
studies in which CD4 effector T cells could be tracked in the
whole animal, Treg cells were found to suppress effector T cell
expansion or homing to lymphoid organs and GVHD target tis-
sues. Tregs that co-expressed high levels of the lymph node hom-
ing receptor, L-selectin, were far more potent than L-selectin lo
cells suggesting that homing of Tregs to secondary lymphoid
organs is critical to preventing alloresponse initiation in vivo. In
other studies, alloengraftment was markedly increased by the in-
fusion of ex vivo activated and expanded donor Treg cells that
expressed high levels of L-selectin. Such engraftment facilitation
was not dependent upon the capacity of host T cells to receive
TGF
 signals. We conclude that the infusion of ex vivo activated
and expanded CD4CD25 is a highly potent means of inhibiting
GVHD and facilitating alloengraftment. Based upon the known
effects of Tregs on suppressing GVHD, augmenting alloengraft-
ment and immune recovery and preserving graft-versus-leukemia
effects, it is clear that a clinical trial of CD425 merits consid-
eration in the context of allogeneic BMT.
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IMMUNE RECONSTITUTION FOLLOWING CORD BLOOD CELL TRANS-
PLANTATION
Weinberg, K. Childrens Hospital, Los Angeles, CA.
Immune reconstitution after hematopoietic stem cell transplan-
tation (HSCT) is a fundamental problem that affects the clinical
outcome of transplantation, regardless of the stem cell source.
Delays or defects in immune reconstitution contribute to suscep-
tibility to infections with viruses, fungi, and encapsulated bacteria,
EBV-lymphoproliferative disease, and possibly to relapse. Ulti-
mately, immune reconstitution depends on generation of new T
lymphocytes in the thymus, a process that depends on interactions
of thymocytes with thymic epithelial cells (TEC). Critical for TEC
support of thymopoiesis are the cytokines IL-7 and kit ligand (KL).
Umbilical cord blood cell transplantation (UCBCT) is increasingly
employed because of theoretical and empiric advantages such as
ready availability and decreased risk of graft-versus-host disease
(GVHD). Some of the features of UCBC that make them attractive
as a source of HSC may also contribute to difﬁculties in immune
reconstitution. However, this is very difﬁcult to analyze critically in
clinical HSCT because of the large number of technical differences
in transplant regimens, alloreactivity, and poorly understood vari-
ables such as donor and host variation in lymphopoiesis. One
approach to understanding the outcome of UCBCT is based on
analyzing the differences between the cellular components of
UCBC vs other sources of stem cells. All stem cell sources contain
mixtures of HSC, committed myeloid and lymphoid progenitors,
and mature lymphocytes. Analyses of myeloid recovery have shown
that HSC dose can be limiting, hence recommendations for a
minimum number of phenotypic progenitor cells required for
marrow recovery. Murine data from our laboratory suggests that
thymic recovery may also be related to the dose of infused HSC or
lymphoid progenitors. Although the number of HSC in UCBC
sources may be limiting, the increased proliferative potential of
cord blood HSC could also be advantageous. Besides reduced
numbers of T lymphocytes in UCBC, a major difference between
UCBC and other HSC sources, e.g., adult marrow or PBSC, is the
nature of the mature T lymphocytes present in each product. The
T lymphocytes in UCBC are predominantly naïve T lymphocytes
while adults have mainly memory T lymphocytes. Naïve T lym-
phocytes require a greater amount of antigen to stimulate in vitro,
compared to memory T lymphocytes. The decreased ability to
stimulate naïve T cells may account for reduced alloreactivity in
UCBC, but may also lead to decreased sensitivity to nominal
antigens such as viruses. Thus, USCBC recipients may gain less
protection from the adoptive transfer of mature T lymphocytes
than BMT or PBSCT recipients. In addition, T lymphocytes from
UCBC may have altered immune responses mediated by the ex-
posure to immunomodulators in the placental microcirculation,
e.g., G-CSF. Over the last ﬁve years, various studies have shown
that the maintenance of mature T lymphocyte numbers in the
periphery is mediated by homeostatic proliferation, in which di-
viding cells do not undergo activation or further maturation. The
mechanism of homeostatic proliferation differs between cell types.
Naïve T lymphocytes depend on self-antigen and IL-7 as signals
for homeostatic proliferation. IL-7 therapy is an attractive strategy
for promoting post-transplant thymopoiesis but may be compli-
cated by exacerbation of GVHD. Recent murine experiments sug-
gest that expansion of mature T lymphocytes by IL-7 may have a
paradoxical inhibitory effect on thymopoiesis. Some approaches
for translation of these experimental concepts into empirical stud-
ies in UCBCT will be described.
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INFECTIOUS DISEASE COMPLICATIONS AFTER UNRELATED DONOR
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN: IM-
PACT OF STEM CELL SOURCE
Barker, J., Wagner, J.E. Blood and Marrow Transplant Program,
University of Minnesota, Minneapolis, MN.
Umbilical cord blood (UCB) is being increasingly used as an
alternative source of hematopoietic stem cells (HSC) for unrelated
donor (URD) transplantation. However, how infection risk after
UCB transplantation (UCBT) compares with that seen after URD
bone marrow (BM) transplantation (BMT) is not known. There-
fore, we conducted a retrospective comparison of serious infectious
complications in the ﬁrst 2 years after HSC transplant in children
transplanted for hematologic malignancy at the University of Min-
nesota. Our hypothesis was that due to HLA disparity, delayed
neutrophil recovery, and the naivety of the neonatal immune sys-
tem, UCBT recipients may be at a higher risk of both early and late
infectious complications compared to recipients of unmanipulated
BM. In this retrospective analysis, there were 136 children (18
years of age) with a hematological malignancy who received cyclo-
phosphamide 120 mg/kg and total body irradiation (TBI 1320-
1375 cGy) followed by the transplantation of unmanipulated bone
marrow (BM, n  52), T cell depleted marrow (TCD, n  24), or
umbilical cord blood (n 60). Overall, the cumulative incidence of
one or more serious infections for the entire period was compara-
ble between groups (BM 81%, TCD 83%, UCB 90%; p  0.12).
Analysis of infection density (episodes of serious infection/1000
patient days) within the time periods days 0-42, 43-100, and 101-
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